Haem Catabolism: Biliverdin and Bilirubin Biochemistry
Haem oxygenase (HO; rate-limiting haem catabolism enzyme; 3 isoforms: HO-1 (HMOX1; inducible; 32 kDa; ER-associated; ubiquitous expression → Nrf2/ARE (primary), NF-κB, HIF-1α, AP-1; induced by: haem, H2O2, NO, heavy metals, shear stress, hypoxia, LPS; rate-limiting degradation: haem + O2 + NADPH → biliverdin IXα + Fe2+ + CO (3 products; stoichiometry: 1 O2 consumed/step; 7 electrons total from NADPH-cytochrome P450 reductase)); HO-2 (constitutive; testes/brain; Gas6; haem sensor); HO-3 (rodent; pseudogene in humans)): biliverdin IXα (green; tetrapyrrole; highly antioxidant; immediate HO-1 product) → biliverdin reductase A (BVR-A; cytosolic; reduces biliverdin IXα → bilirubin IXα (yellow; lipophilic; potent peroxyl radical chain-breaker; cyclic antioxidant: bilirubin → oxidised → biliverdin → BVR-A → bilirubin: catalytic at nM; 10,000× amplification vs stoichiometric antioxidants); BVR-A also: PI3K/Akt Ser308 Akt phosphorylation, MEK/ERK activator, insulin signalling modulator)); bilirubin disposition: unconjugated bilirubin (UCB; lipophilic; albumin-bound in plasma (Ka ~10^7 M−1; 1 high-affinity site; free UCB <1 nM cytoprotective; free UCB >25 µM neurotoxic (kernicterus in neonates))) → hepatocyte OATP1B1/1B3 uptake → UGT1A1 (bilirubin UDP-glucuronosyltransferase; Nrf2/AhR regulated) → bilirubin diglucuronide (BDG; water-soluble; biliary excretion via MRP2/ABCC2 → bile → intestine → urobilinogen).
Spirulina Mechanisms in Biliverdin/Bilirubin Biology
Nrf2-HO-1 Induction: Biliverdin/CO Production
HO-1 (HMOX1; the most robustly Nrf2-induced gene; HMOX1 promoter contains: proximal ARE (nGRE/NF-E2-like; TGACTCAGC); distal stress-responsive element (StRE; AP-1 + NF-E2); Nrf2/MafK heterodimer binds ARE Cys151/288/273 Keap1-released Nrf2; HO-1 +35–50% protein (Western blot/ELISA) in LPS/H2O2-challenged macrophage/HMEC-1 endothelial models) is induced by spirulina: (1) Phycocyanobilin (PCB; open-chain tetrapyrrole; structural BVR-A substrate mimic; PCB also directly activates Nrf2 via Keap1 BTB domain alkylation at Cys151 → maximum HO-1 induction); (2) β-carotene/zeaxanthin singlet oxygen quenching → reduced haem photooxidation demand on HO-1; (3) AMPK → Nrf2 (AMPK-mediated Nrf2 Ser558 phosphorylation → nuclear retention → HMOX1 promoter binding). HO-1 products: (a) Biliverdin → BVR-A → bilirubin (catalytic antioxidant cycle); (b) CO (anti-inflammatory: sGC → cGMP → PKG → p38 MAPK inhibition; AMPK activation: CO → mitochondrial Complex II inhibition → AMP:ATP → AMPK; HIF-1α stabilisation; NF-κB suppression via CO → soluble guanylyl cyclase/cGMP → IκBα stabilisation); (c) Fe2+ → ferritin (Nrf2 → ferritin H/L chain → Fe2+ sequestration → Fenton reaction prevention → •OH suppression).
BVR-A Redox Cycling and Bilirubin Antioxidant Activity
BVR-A (biliverdin reductase A; cytosolic; dual specificity: biliverdin IXα/β; NADPH/NADH; Km biliverdin ~0.5 µM; Km NADPH ~10 µM; high catalytic efficiency; 37 kDa; serine/threonine/tyrosine kinase activity: BVR-A pSer/pThr → Akt Ser308 direct phosphorylation; also PI3K regulatory subunit binding; BVR-A → MEK1 → ERK1/2 Thr202/Tyr204; BVR-A is not just a reductase but a scaffold/kinase hub in insulin/growth factor signalling)) enables the biliverdin ↔ bilirubin antioxidant cycle: bilirubin (peroxyl radical scavenging: bilirubin + 2ROO• → biliverdin + ROOH; first-order rate constant k ~10^4 M−1s−1 in membranes; amplified by albumin-mediated delivery; physiological [bilirubin] 5–17 µM provides continuous membrane peroxyl quenching) → biliverdin (re-reduced by BVR-A → bilirubin: catalytic cycle; 1 bilirubin molecule can quench ~10,000 peroxyl radicals via this cycle). Spirulina NAD(P)H support (AMPK → NAMPT → NAD+ regeneration; Nrf2 → G6PD/ME1 → NADPH production) maintains BVR-A substrate availability for continuous bilirubin regeneration. Additionally, phycocyanobilin (structural analogue of biliverdin) may serve as a BVR-A substrate: PCB → phycocyanorubin (reduced form) → direct antioxidant at membrane level (analogous to biliverdin→bilirubin).
UGT1A1 Nrf2/AhR Upregulation: Conjugation Safety
UGT1A1 (bilirubin UDP-glucuronosyltransferase 1A1; hepatic ER membrane; TATA-box promoter element; regulated by: Nrf2/ARE (ARE2 site at −700 bp; Nrf2 binds ARE2 → UGT1A1 +20–30%); AhR (xenobiotic response element (XRE) in UGT1A1 promoter; AhR/ARNT → UGT1A1 (the basis for pharmacological induction by rifampin/phenobarbital)); PPARα (partial activation); polymorphism: UGT1A1*28 (TA7 promoter; Gilbert syndrome; −60–70% UGT1A1 activity → mildly elevated UCB; linked to lower CVD risk); function: bilirubin + 2 UDP-GlcA → bilirubin diglucuronide (BDG; water-soluble; MRP2 biliary transport)) is upregulated by spirulina: (1) Nrf2 ARE2 binding → UGT1A1 +20–30% (protective: ensures elevated HO-1-derived bilirubin is efficiently conjugated; prevents unconjugated hyperbilirubinemia); (2) AhR activation by indole metabolites (spirulina Trp → gut microbiome → indole/IAA/IPA → AhR → XRE → UGT1A1); (3) PPARα (spirulina omega-6 FADS2 → GLA → PPARα partial activation → UGT1A1 co-induction). Net: HO-1-driven bilirubin elevation safely handled by upregulated UGT1A1; optimal physiological range → maximal antioxidant, minimal toxicity.
CO-Mediated Anti-inflammatory Signalling
Carbon monoxide (CO; HO-1 by-product; endogenous gasotransmitter; cytoprotective at low concentrations (nM–µM); toxic at high concentrations (ppm); CO signalling: (1) sGC (soluble guanylyl cyclase; haem-Fe2+ → CO/NO binding → cGMP 4–20-fold elevation; CO has lower potency than NO for sGC activation (~0.1-fold) but longer duration; cGMP → PKG → vasodilation, platelet inhibition, NF-κB suppression); (2) Mitochondrial Complex IV inhibition (CO binds CuB → reduced ETC flux → mild ROS → AMPK; also → mitochondrial biogenesis (PGC-1α) paradoxically at low CO); (3) p38 MAPK activation (CO → p38 → IL-10 → anti-inflammatory; different from LPS-driven p38 → inflammatory IL-12); (4) SIRT1 (CO → mitochondrial uncoupling → NAD+ → SIRT1 → NF-κB deacetylation → p65 K310Ac reduced → anti-inflammatory)) from spirulina HO-1 induction: CO production in proportion to HO-1 activity; endogenous CO from spirulina-induced HO-1 → NF-κB −20–30% in macrophage/endothelial LPS models; sGC/cGMP → vascular tone modulation; synergy with eNOS-derived NO (CO and NO share sGC target).
Clinical Outcomes in Biliverdin/Bilirubin Biology
- HO-1 protein (HMOX1; macrophage/endothelial models): +35–50%
- Serum bilirubin (total; unconjugated; plasma): +5–15%
- UGT1A1 mRNA (hepatocyte; Nrf2/AhR): +20–30%
- 8-isoprostane (lipid peroxidation; bilirubin-scavenged): −20–35%
- IL-6 (CO/HO-1 anti-inflammatory): −20–30%
- Ferritin (Fe2+ sequestration; HO-1 co-product): +15–25%
Dosing and Drug Interactions
Oxidative stress/cardiovascular: 5–10g daily for 8–16 weeks. Statins (CVD; modest HO-1 induction): Statin HO-1 via Nrf2 (KLF2 → HO-1) is complementary to spirulina Nrf2-HO-1; additive cytoprotection. Phenobarbital/rifampicin (UGT1A1 inducers): Pharmacological UGT1A1 induction + spirulina Nrf2/AhR-UGT1A1: complementary; relevant for UGT1A1*28 Gilbert patients with elevated UCB. Irinotecan (UGT1A1 substrate; SN-38 glucuronidation): Spirulina UGT1A1 upregulation may increase SN-38 glucuronidation → potentially reduced SN-38 toxicity; monitor in oncology context (UGT1A1*28 patients at higher irinotecan toxicity risk). Atazanavir (UGT1A1 inhibitor; HIV): Atazanavir inhibits UGT1A1 → hyperbilirubinemia; spirulina Nrf2-UGT1A1 upregulation may partially counteract; monitor total bilirubin. Summary: HO-1 +35–50%, bilirubin +5–15%, UGT1A1 +20–30%, 8-isoprostane −20–35%; dosing 5–10g daily. NK concern: low.